RUNX1 and hyperlipidemia: Indeed, injecting the human APOC2 mimetic peptide CII-a, but not its inactive analog CII-i, rescued the hyperlipidemia and anemia phenotype at 6.3 dpf (Fig. 4a–d) and, importantly, restored both cmyb/runx1 and beta-globin expression at 3.3 dpf (Fig. 4e) in apoc2 mutants.